1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. DNA/RNA Synthesis

DNA/RNA Synthesis

RNA synthesis, which is also called DNA transcription, is a highly selective process. Transcription by RNA polymerase II extends beyond RNA synthesis, towards a more active role in mRNA maturation, surveillance and export to the cytoplasm.

Single-strand breaks are repaired by DNA ligase using the complementary strand of the double helix as a template, with DNA ligase creating the final phosphodiester bond to fully repair the DNA.DNA ligases discriminate against substrates containing RNA strands or mismatched base pairs at positions near the ends of the nickedDNA. Bleomycin (BLM) exerts its genotoxicity by generating free radicals, whichattack C-4′ in the deoxyribose backbone of DNA, leading to opening of the ribose ring and strand breakage; it is an S-independentradiomimetic agent that causes double-strand breaks in DNA.

First strand cDNA is synthesized using random hexamer primers and M-MuLV Reverse Transcriptase (RNase H). Second strand cDNA synthesis is subsequently performed using DNA Polymerase I and RNase H. The remaining overhangs are converted into blunt ends using exonuclease/polymerase activity. After adenylation of the 3′ ends of DNA fragments, NEBNext Adaptor with hairpin loop structure is ligated to prepare the samples for hybridization. Cell cycle and DNA replication are the top two pathways regulated by BET bromodomain inhibition. Cycloheximide blocks the translation of mRNA to protein.

DNA/RNA Synthesis Related Products (93):

Cat. No. Product Name Effect Purity
  • HY-12320
    Cycloheximide Inhibitor 99.86%
    Cycloheximide (Naramycin A) is an eukaryote protein synthesis inhibitor, with IC50s of 532.5 nM and 2880 nM for protein synthesis and RNA synthesis in vivo, respectively.
  • HY-17559
    Actinomycin D Inhibitor 99.58%
    Actinomycin D inhibits DNA repair with an IC50 of 0.42 μM.
  • HY-13316
    Mitomycin C Inhibitor 99.45%
    Mitomycin C is an antitumor drug and antibiotic that shows extraordinary ability to inhibit DNA synthesis. Mitomycin C is a DNA cross-linking agent, which induces DNA damaging.
  • HY-17026
    Gemcitabine Inhibitor 99.92%
    Gemcitabine (NSC 613327;LY188011) is a DNA synthesis inhibitor which inhibits the growth of BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM, respectively.
  • HY-17565
    Bleomycin sulfate Inhibitor >98.0%
    Bleomycin sulfate is a DNA synthesis inhibitor with potent antitumor activity.
  • HY-14768
    Favipiravir Inhibitor 98.89%
    Favipiravir (T-705) is a novel viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with IC50 of 341 nM.
  • HY-16350
    NKP-1339 Inhibitor
    NKP-1339 (IT-139) is the first-in-class ruthenium-based anticancer drug in clinical development against solid cancer with limited side effects. NKP-1339 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. NKP-1339 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu.
  • HY-126214
    JH-RE-06 Inhibitor >98.0%
    JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy.
  • HY-13753
    Streptozocin Inhibitor 99.58%
    Streptozocin is a potent DNA-methylating antibiotic. Streptozotocin causes methylation of liver and kidney and pancreatic DNA, but no methylation in brain DNA.
  • HY-13605
    Cytarabine Inhibitor 99.99%
    Cytarabine, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM.
  • HY-19610
    alpha-Amanitin Inhibitor 99.79%
    alpha-Amanitin is the principal toxin of several deadly poisonous mushrooms, exerting its toxic function by inhibiting RNA-polymerase II.
  • HY-17393
    Carboplatin Inhibitor 99.93%
    Carboplatin (NSC 241240) is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death. Carboplatin (NSC 241240) is a derivative of CDDP and a potent anti-cancer agent.
  • HY-18982
    Anisomycin Inhibitor 98.20%
    Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. Anisomycin is a JNK activator, which increases phospho-JNK.
  • HY-B0003
    Gemcitabine Hydrochloride Inhibitor 99.93%
    Gemcitabine (Hydrochloride) is a DNA synthesis inhibitor with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM in BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells, respectively.
  • HY-13062
    Daunorubicin Hydrochloride Inhibitor 99.37%
    Daunorubicin Hydrochloride (RP 13057 Hydrochloride) is a topoisomerase II inhibitor with potent antineoplastic activities. Daunorubicin Hydrochloride (RP 13057 Hydrochloride) inhibites DNA and RNA synthesis in sensitive and resistant Ehrlich ascites tumor cells.
  • HY-12742
    SCR7 Inhibitor 99.75%
    SCR7 is a DNA Ligase IV inhibitor with anticancer activity and is also a CRISPR HDR enhancer which increases the efficiency of Cas9-mediated HDR.
  • HY-B0016
    Capecitabine Inhibitor 99.97%
    Capecitabine is an oral prodrug that is converted to its active metabolite, 5-FU, by thymidine phosphorylase.
  • HY-B0313
    Hydroxyurea Inhibitor >98.0%
    Hydroxyurea is a cell apoptosis inducer that inhibit DNA synthesis through inhibition of ribonucleotide reductase.
  • HY-13323
    CX-5461 Inhibitor 98.39%
    CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC50s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively.
  • HY-19620
    Branaplam Agonist 99.67%
    Branaplam (LMI070) is a highly potent, selective and orally active small molecule SMN2 splicing modulator.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.